Adverum Biotechnologies Inc

Adverum Biotechnologies Inc. is a clinical-stage biotechnology company headquartered in Redwood City, California. The company employs 182 individuals and reported $7.5 million in revenue. Adverum Biotechnologies trades on the NASDAQ stock exchange under the ticker symbol ADVM. Adverum focuses on developing innovative gene therapies to address prevalent ocular diseases. Their primary goal is to establish gene therapy as a new standard of care, aiming to cure eye diseases and prevent blindness. The company's proprietary intravitreal (IVT) platform enables the development of durable, single-administration therapies for convenient treatment in physicians' offices. This eliminates the need for frequent ocular injections, improving patient experience and adherence to treatment. Adverum's leading gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022), is being investigated as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration. This groundbreaking approach aims to overcome the limitations of current treatment methods, offering a transformative solution for these debilitating eye conditions. For more information about Adverum Biotechnologies Inc., please visit their website at adverum.com.